ORETICYL 25 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Oreticyl 25, and when can generic versions of Oreticyl 25 launch?
Oreticyl 25 is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in ORETICYL 25 is deserpidine; hydrochlorothiazide. There are four drug master file entries for this compound. Additional details are available on the deserpidine; hydrochlorothiazide profile page.
Summary for ORETICYL 25
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ORETICYL 25 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ORETICYL 25
US Patents and Regulatory Information for ORETICYL 25
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | ORETICYL 25 | deserpidine; hydrochlorothiazide | TABLET;ORAL | 012148-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |